Langer, Inc. Announces Sale of Langer UK Ltd. to a Subsidiary of Sole Solutions;...

Langer, Inc. Announces Sale of Langer UK Ltd. to a Subsidiary of Sole Solutions;
Silipos Inc. Forms Strategic Partnership With Sole Solutions and Langer UK

DEER PARK, New York, Jan. 18, 2008 (PRIME NEWSWIRE) -- Langer, Inc.
(Nasdaq:GAIT) ("Langer" or the "Company") today announced sale of the stock of
Langer UK Ltd. ("Langer UK") to an affiliate of Sole Solutions Ltd. ("Sole
Solutions"), a retailer of specialist footwear based in the United Kingdom. The
sale price was approximately GBP 587,500, with GBP 475,000 paid in cash at
closing and the remainder paid through the receipt of a note in the amount of
GBP 112,500. The note matures in two years, bears interest at a rate of 8.5% per
annum and is secured by the personal guarantee of an affiliate of the purchaser.
In addition, in connection with the transaction, Silipos Inc. ("Silipos"), a
wholly owned subsidiary of Langer, formed a strategic partnership with Sole
Solutions and Langer UK through which Sole Solutions and Langer UK will provide
sales, marketing and distribution support as Silipos' exclusive strategic
partner to the medical markets in the United Kingdom and European Union.

Gray Hudkins, President and CEO of Langer, commented: "We are pleased to have
completed this first step in connection with our previously announced review of
strategic alternatives in such a way that simplifies our business and provides
for the future of Langer UK through the combination with Sole Solutions. We are
also excited to be adding Sole Solutions as a new strategic partner in our
Silipos business. Langer UK is expected to continue to spearhead our sales and
marketing, customer service and distribution activities with medical
distributors in Europe, and the combination with Sole Solutions will enhance the
level of service we provide to the marketplace, ensuring a seemless transition
through this transaction and positioning the Silipos business for growth in the
future."

Adrian Bishop, Managing Director for Langer UK, commented: "On behalf of Langer
UK, we are looking forward to joining forces with Sole Solutions to continue our
track record of organic growth in our markets and working together to expand the
Langer UK, Silipos and Sole Solutions businesses. We believe our continued
partnership with Silipos will allow us to continue our tradition of providing
innovative products and excellent service to our customers in our key markets."

Langer, Inc., together with its wholly owned subsidiaries Silipos, Inc. and
Regal Medical, Inc., is a leading provider of high quality medical products and
services targeting the long-term care, orthopedic, orthotic and prosthetic
markets. Through its wholly owned subsidiaries Twincraft, Inc. and Silipos,
Inc., the Company offers a diverse line of bar soap and other skincare products
for the private label retail, medical and therapeutic markets. The Company sells
its medical products primarily in the U.S. and Canada, and in more than 30 other
countries, to national, regional, international and independent medical
distributors and directly to healthcare professionals and patients. The Company
sells its personal care products to branded consumer products companies, direct
marketers, distribution partners, and specialty retailers, among others. Langer
is based in Deer Park, NY and has additional manufacturing facilities in Niagara
Falls, NY, Winooski, VT, Montreal, Canada, and sales and marketing offices in
Toronto, Canada, King of Prussia, PA and New York, NY.

Certain matters discussed in this press release constitute forward-looking
statements that involve risks and uncertainties that could cause actual results
to differ materially from those projected. The Company may use words such as
"anticipates," "believes," "plans," "expects," "intends," "future" and similar
expressions to identify forward-looking statements. These risks and
uncertainties, relating to both ongoing operations and acquisitions, are
described in the Company's filings with the Securities and Exchange Commission,
including its 2006 Form 10-K and most recently filed Form 10-Qs and Form 8-Ks
and Form S-1. With respect to our planned study of strategic alternatives, there
can be no assurance that it will result in any specific transaction, any change
of our strategies, or any enhancement of shareholder value.

-0-
CONTACT: Langer, Inc.
W. Gray Hudkins, President and CEO
(212) 687-3260